SAN FRANCISCO — Treatment with ranibizumab led to improvement in diabetic retinopathy severity scores in a subanalysis of RISE and RIDE data, a speaker here said.
“My objective in this subanalysis of RIDE and RISE was to evaluate the effect of ranibizumab in eyes at particularly high risk of progression to [proliferative diabetic retinopathy] in the near-term future, focusing on those with a retinopathy severity level of 47 to 53, and to consider the role of baseline characteristics and macular nonperfusion on outcomes among this particular group,” Charles Wykoff, MD, PhD, said at the American Society of Retina Specialists annual meeting.
Charles Wykoff, MD, PhD
In the prior open-label extension period, stable or improved retinopathy was seen in 75% of patients in the 47 to 53 score group in patients receiving as-needed Lucentis (ranibizumab, Genentech), Wykoff said.
“The retinopathy severity improvements achieved during RIDE and RISE overall were maintained during the open-label extension,” Wykoff said. “On the flipside, 25% to 40% of patients did experience some amount of retinopathy severity worsening.”
Wykoff evaluated baseline characteristics correlated with the 75% of patients who achieved two or more steps of retinopathy improvement among this high-risk 47 to 53 score population compared with those who did not.
Characteristics that were not predictive of retinopathy severity improvement included central foveal thickness, best corrected visual acuity, duration of diabetes, diabetic retinopathy sublevels and change in vision at 3 months.
With regard to macular nonperfusion, Wykoff said, “The presence or absence of macular nonperfusion at baseline did not appear to impact the proportion of patients that achieved at least two steps of retinopathy severity improvement.” – by Patricia Nale, ELS
Wykoff C. Ranibizumab induces regression of diabetic retinopathy (DR), prevents retinal nonperfusion in patients at high risk of conversion to proliferative DR. Presented at: American Society of Retina Specialists annual meeting; Aug. 9-14, 2016; San Francisco.
Disclosure: Wykoff reports he is a consultant for Alcon, Allergan, Alimera, Bayer, Genentech, Regeneron, Roche, ThromboGenics and Valeant; is a speaker for Allergan and Regeneron; and receives research support from Alcon/Novartis, Allegro Ophthalmic, Allergan, Apellis Pharmaceuticals, DRCR.net, Iconic Therapeutics, Genentech/Roche and Regeneron/Bayer.